Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLY: Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy
NCT05172934Phase 2Completed
- Sponsor
- Promedica International
- Start
- Apr 2022
- Primary completion
- Sep 2023
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tenecteplase in ischemic stroke, sponsored by Promedica International. Primary endpoint: Incidence of Any Intracranial Hemorrhage and Neurologic Worsening at 24 hours. Started Apr 2022; status: completed.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05172934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05172934.